abstractthat
adhes
molecul
play
major
role
regul
normal
hematopoiesi
suggest
abund
molecul
present
earli
bone
marrow
progenitor
cell
differenti
pattern
express
discret
stage
differenti
along
variou
cell
lineag
particular
precursor
cell
matrixendotheli
interact
determin
retain
releas
hematopoiet
cell
bone
marrow
microenviron
consequ
chang
affin
quantit
express
adhes
molecul
either
bone
marrow
stroma
blood
cell
precursor
compon
normal
develop
due
activ
malign
process
affect
cell
attach
adhes
molecul
therefor
modul
molecul
alter
biolog
behavior
normal
leukem
hematopoiet
cell
primarili
term
migrat
local
properti
although
also
particip
mani
cell
function
cytotox
antigen
present
bind
virus
cancer
cell
sever
membranebound
adhes
molecul
instanc
solubl
counterpart
may
biolog
activ
describ
acut
myeloid
leukemia
potenti
diagnost
physiolog
signific
leukocyt
antigen
adhes
properti
address
comment
copyright
elsevi
scienc
ltd
key
word
adhes
molecul
acut
myeloid
leukemia
knowledg
adhes
molecul
express
hematopoiet
endotheli
cell
constantli
expand
partli
increas
report
identifi
establish
leukocyt
antigen
adhes
molecul
interact
ligand
recent
exampl
character
stem
cell
antigen
sialomucin
promot
cell
adhes
via
olink
carbohydr
moieti
may
function
ligand
lselectin
review
l
anoth
cellassoci
mucin
leukosialin
counterreceptor
intercellular
adhes
molecul
icam
review
panmyeloid
antigen
member
sialoadhesin
famili
togeth
bcell
antigen
follow
although
studi
publish
address
express
andor
potenti
biolog
clinic
signific
adhes
molecul
acut
leukemia
per
se
eg
studi
kawada
et
al
mani
studi
alreadi
exist
antigen
recent
recogn
cellular
interact
properti
new
leukemia
syndrom
emerg
predominantli
among
acut
myeloid
leukemia
aml
base
biolog
properti
may
relat
presenc
adhes
molecul
discern
particular
subtyp
otherwis
morpholog
often
immunophenotyp
sometim
even
cytogenet
ident
leukemia
molecul
neuralcel
adhes
molecul
ncam
implic
propens
cell
contain
transloc
local
extramedullari
site
l
conjunct
vascular
cell
adhes
molecul
correl
dermal
infiltr
leukem
cell
poorli
differenti
fabml
monocyt
leukemia
fabm
molecul
well
express
e
endotheli
selectin
human
endothelium
e
paietta
side
permit
product
interact
respect
ligand
aml
blast
cell
name
late
activ
integrin
sialyl
lewi
x
antigen
respect
possibl
contribut
transendotheli
migrat
leukem
cell
establish
extravascular
diseas
also
character
novel
aml
subtyp
term
myeloidnatur
killer
nk
cell
acut
leukemia
cytolog
resembl
lack
immunophenotyp
myeloidnk
blast
lack
hladr
acut
promyelocyt
leukemia
apl
cell
express
absenc
anoth
natur
killer
cell
antigen
cdlla
potenti
clinic
valu
manag
apl
patient
may
membranebound
aminopeptidas
n
serv
receptor
coronavirus
link
invas
properti
tumor
cell
correl
develop
lifethreaten
retino
acid
syndrom
extent
hyperleukocytosi
alltrun
retino
acid
therapi
presenc
pant
cell
antigen
member
immunoglobulin
gene
superfamili
cellular
adhes
protein
counterstructur
anoth
member
famili
suggest
associ
short
form
pmlrarcr
transcript
propos
molecular
marker
impair
respons
durat
surviv
apl
review
l
hand
express
character
immunophenotyp
patient
favor
aml
associ
inv
karyotyp
express
aml
gener
found
correl
significantli
express
myelomonocyt
antigen
cdllb
prototyp
monocyt
antigen
although
adhes
molecul
surfac
monocyt
mediat
adher
cdllb
ligand
endotheli
cell
suggest
differenti
adhes
properti
earli
cdllb
vs
late
cdllb
stage
monocyt
develop
larg
studi
eastern
cooper
oncolog
group
immatur
acut
monocyt
leukemia
amol
character
cdllb
posit
absenc
recent
demonstr
significantli
inferior
prognosi
term
remiss
achiev
matur
amol
maturationdepend
modul
intercellular
adhes
molecul
affect
potenti
mediat
cellular
interact
report
sialic
acid
depend
adhes
via
appli
lectincarbohydr
recognit
selectin
ligand
glycosyltransferas
development
regul
therebi
control
pattern
carbohydr
residu
myeloid
cell
structur
variou
stage
differenti
thu
bind
antibodi
use
recogn
presenc
select
adhes
molecul
may
affect
subtl
differ
glycosyl
respect
antigen
effici
adhes
mediat
antigen
may
entir
differ
depend
upon
oligosaccharid
structur
hand
variabl
antibodi
reactiv
pattern
antibodi
latter
recogn
sialyl
epitop
use
differenti
diagnosi
apl
yet
unexplor
term
diagnost
biolog
signific
glycosylationdepend
distribut
epitop
differ
antibodi
reactiv
seen
among
aml
well
leukem
normal
precursor
cell
suggest
activ
glycosyltransferas
affect
heavili
glycosyl
cell
surfac
sialomucin
regul
maturationdifferenti
stage
hematopoiet
cell
cytoadhes
properti
posit
cell
vari
state
epitop
support
propos
role
ligand
given
known
sensit
antibodi
other
analog
properti
epitop
carbohydr
composit
propos
predict
role
aml
must
view
context
antibodi
sourc
may
explain
discrep
data
report
literatur
express
profil
adhes
antigen
may
contribut
novel
function
classif
system
aml
intrigu
concept
may
lead
subtypespecif
therapi
antigen
known
date
offer
similar
opportun
noteworthi
would
pglycoprotein
multidrug
resist
mediat
adhes
molecul
acut
myeloid
leukemia
pglycoprotein
modul
alreadi
found
way
clinic
pglycoprotein
clinicobiolog
relev
aml
found
correl
express
specif
cytogenet
abnorm
l
well
type
therapeut
regimen
employ
similar
associ
begin
disclos
adhes
molecul
aml
base
experi
studi
clinic
valu
cytoadhes
antigen
aml
rather
consid
antigen
independ
biolog
entiti
need
incorpor
prognost
implic
immunophenotyp
well
karyotyp
featur
care
control
patient
popul
compar
treatment
order
inform
